We further show that GMCL1 loss sensitizes p53-wild-type, but not p53-mutant, cancer cells to paclitaxel-induced death, suggesting that GMCL1 inhibition may offer a selective therapeutic strategy for tumors with intact p53 function. Here, TP53 is linked to cancer.